Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.22 AUD | -2.46% | -0.05% | -22.95% |
24/04 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
23/04 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.95% | 1.66B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- FDA Approves Phase 2 Clinical Trial for Neuren Pharmaceuticals' Prader-Willi Syndrome Drug